In the second largest M&A deal of the year, Merck & Co. Inc. has strengthened its cardiopulmonary portfolio with the $10 ...

Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

Researchers at the Chinese Academy of Sciences and collaborators have developed a new method to label and monitor dormant breast cancer cells over time, shedding light on how these cells survive ...

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...

ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...

US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...

Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...

The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.

ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...

Over the last 7 days, the United States market has remained flat, though it is up 13% over the past year with an optimistic forecast for earnings growth. In such a landscape, identifying stocks with ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...